>>14263296 (pb)
>Collectively, these findings provide compelling circumstantial evidence that endogenous reverse transcriptase converts SARS-CoV-2 RNA into DNA and this DNA, in turn, becomes integrated into the host cell’s genome.
Saucehttps://reasons.org/explore/blogs/the-cells-design/sars-cov-2-biology-gives-insight-into-role-of-endogenous-retroviruses-in-genomes
tysob
>she shot him in the face
WHY did she shoot him? Was it in self defense, or is she just a crazy psycho chick who got tired of his shit?
They reiterate the obvious fact of the matter, then decorate it with subtle innuendo to craft a perception of it.
> shill slide
It has that eyeroll response built in, but it's oddly comforting.
/ourshills/
>https://pubmed.ncbi.nlm.nih.gov/33278625/
Randomized Controlled Trial Int J Infect Dis
. 2021 Feb;103:214-216. doi: 10.1016/j.ijid.2020.11.191. Epub 2020 Dec 2.
A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness
Sabeena Ahmed 1, Mohammad Mahbubul Karim 1, Allen G Ross 1, Mohammad Sharif Hossain 1, John D Clemens 1, Mariya Kibtiya Sumiya 1, Ching Swe Phru 1, Mustafizur Rahman 1, Khalequ Zaman 1, Jyoti Somani 2, Rubina Yasmin 3, Mohammad Abul Hasnat 4, Ahmedul Kabir 5, Asma Binte Aziz 1, Wasif Ali Khan 6
Affiliations expand
PMID: 33278625 PMCID: PMC7709596 DOI: 10.1016/j.ijid.2020.11.191
Free PMC article
Abstract
Ivermectin, a US Food and Drug Administration-approved anti-parasitic agent, was found to inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in vitro. A randomized, double-blind, placebo-controlled trial was conducted to determine the rapidity of viral clearance and safety of ivermectin among adult SARS-CoV-2 patients. The trial included 72 hospitalized patients in Dhaka, Bangladesh, who were assigned to one of three groups: oral ivermectin alone (12 mg once daily for 5 days), oral ivermectin in combination with doxycycline (12 mg ivermectin single dose and 200 mg doxycycline on day 1, followed by 100 mg every 12 h for the next 4 days), and a placebo control group. Clinical symptoms of fever, cough, and sore throat were comparable among the three groups. Virological clearance was earlier in the 5-day ivermectin treatment arm when compared to the placebo group (9.7 days vs 12.7 days; p = 0.02), but this was not the case for the ivermectin + doxycycline arm (11.5 days; p = 0.27). There were no severe adverse drug events recorded in the study. A 5-day course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19. Larger trials will be needed to confirm these preliminary findings.
Keywords: Bangladesh; COVID-19; Doxycycline; Ivermectin; SARS-CoV-2.
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
The authors declare that there are no known competing financial interests or personal relationships that could have appeared to influence the work described in this paper.